Dr. Awan Discusses Challenges With Ibrutinib in CLL

Farrukh Awan, MBBS
Published: Monday, Oct 16, 2017



Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

The key issues with usage of ibrutinib in patients with CLL are duration and the management of side effects.

Current ongoing trials are tackling these challenges, says Awan, results of which will hopefully bring more knowledge to the field.
 


Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

The key issues with usage of ibrutinib in patients with CLL are duration and the management of side effects.

Current ongoing trials are tackling these challenges, says Awan, results of which will hopefully bring more knowledge to the field.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x